Mouse Interleukin-4 (mIL-4) #5208
We recommend the following alternatives
#
Product Name
Inquiry Info. # 5208
Please see our recommended alternatives.
Product Information
Product Usage Information
With carrier: Add sterile PBS or PBS containing 1% bovine or human serum albumin or 5-10% FBS to a final mIL-4 concentration of greater than 50 μg/ml. Solubilize for 30 minutes at room temperature with occasional gentle vortexing.
Carrier free: Add sterile PBS or PBS containing protein to minimize absorption of mIL-4 to surfaces. Solubilize for 30 minutes at room temperature with occasional gentle vortexing. Stock mIL-4 should be greater than 50 μg/ml.
Formulation
Storage
Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
Product Description
| MW (kDa) | 16 |
| Purity | >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mIL-4. All lots are greater than 98% pure. |
| Endotoxin | Less than 0.01 ng endotoxin/1 μg mIL-4. |
| Activity | The bioactivity of recombinant mIL-4 was determined in an HT-2 cell proliferation assay. The ED50 of each lot is between 100-400 pg/ml. |
| Molecular Formula | Recombinant mIL-4 contains no "tags" and the nonglycosylated protein has a calculated MW of 13,557. DTT-reduced and non-reduced protein migrate as 16 kDa polypeptide due to glycosylation. The expected amino-terminal HIHGC of recombinant mIL-4 was verified by amino acid sequencing. |
Source / Purification
Recombinant mouse IL-4 (mIL-4) His21-Ser140 (Accession #NP_067258) was expressed in human 293 cells at Cell Signaling Technology.
Background
IL-4 is produced by T cells, NK T cells, γδ cells, and mast cells (1). Target cells include B cells, T cells, and macrophages (1). IL-4 induces the polarization of naïve helper T cells into the TH2 phenotype (1,2). IL-4 also promotes B cell proliferation, antibody class switching and the production other TH2 cytokines including IL-5 and IL-9. IL-4 induced TH2 polarization is important in developing humoral immunity against extracellular pathogens (1) and is involved in the development of allergy and asthma (3). IL-4 binds to two distinct receptors, the Type I receptor and Type II receptor. Type I receptor is a heterodimer consisting of IL-4Rα chain and the common gamma chain, γc (4,5). Type II receptor, which is shared with IL-13, is a heterodimer of IL-4Rα and IL-13Rα1. Signaling initiated via Type I receptor results in the activation of Jak1/Stat6, Jak3 and the PI3K/Akt pathways (4). The Type II receptor activates the Jak1/Stat6 and the Tyk2/Stat3 pathways (4).
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.